updat estim ponder
test higher throughput faster turnaround
recent announc assay detect
develop autom open access panther fusion system
instal global us hh subsequ said would provid
acceler holx test develop design process
test hour deliv result less hour vs day ldt
also expect ivd provid make test avail molecular
diagnost mdx platform along ldt help allevi test
burden said think financi benefit test hard
defin may outweigh headwind elsewher
factor capital-expenditure ou exposur elect volum
yet seen weak hospit capital-expenditure sinc recess
purpos diversifi away capit equip limit exposur convers
cycl us capit equip purchas breast health less
overal outsid us ou revenu exposur china
much lower ivd peer like limit
virus-rel impact although recent infect increas us/eu could
impact depend mammographi volum dx test volum
could hurt elect diagnost test leader sti test cytolog
 pap smear diminish detail separ diagnost note
updat estim lower po
lower sale vs guid
specif lower organ revenue growth estimate ex cynosur blood
vs guidanc rang potenti challeng
also tweak margin assumpt result adj ep vs
current guidanc lower po base
reflect med-tech dx group multipl compress ep estimate
line peer reiter buy rate given attract valuat
full definit iqmethod sm measur see page
bofa secur seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
hh us depart
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
lead manufactur medic
devic product focus heathcar need
mammographi breast biopsi earli stage
treatment remov uterin fibroid
core mammographi diagnost
busi deliv solid perform
believ steadier
foot organ growth upsid due
expand offer breast health strength
molecular diagnost mdx busi
believ cynosur cyno headwind less
controversi stock may allow
stock rerat investor focu
past year shift away capit limit exposur
convers cycl revenu base came capit
equip sale primarili mammographi system dx instrument exclud
cynosur laser see chart theoret capital-expenditure spend prioriti shift
outbreak mammographi system would see temporari neg impact
holx test develop would direct benefit panther fusion placement
time current panther instal base fusion compon
chart sale mix exclud cynosur revenu recur
recent compani comment
list recent manag comment situat
under-index intern china total revenu extent
exposur think quit manag well pretti small presenc
japan itali think meaning impact quarter
suppli chain perspect limit direct exposur china
analyz situat get second third tier potenti delay
noth go impact current quarter realli impact
smaller scale busi limit risk
seen impact either bigger market play europ us
certainli evolv potenti escal situat extent
women may stop well visit seen yet
might start see impact
po base approxim calendar ep estim
line diagnost med-tech peer multipl believ multipl
justifi given organ growth strength breast molecular diagnost
upsid risk po faster growth core diagnost mammographi
gynecolog surgeri end market synergi addit tuck-in deal
downsid risk po competit pressur slower uptak reimburs
new product unfavor chang clinic practic guidelin manag
departur regulatori risk faster declin legaci busi
ivi herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
us life scienc diagnost tool anim health coverag cluster
qualiti earn
iqmethod smi set bofa global research standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa global research
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
